U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C14H16N4
Molecular Weight 240.3036
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of BUDRALAZINE

SMILES

CC(C)=CC(C)=NNC1=C2C=CC=CC2=CN=N1

InChI

InChIKey=DQGFCLJXYFXXIJ-LFIBNONCSA-N
InChI=1S/C14H16N4/c1-10(2)8-11(3)16-18-14-13-7-5-4-6-12(13)9-15-17-14/h4-9H,1-3H3,(H,17,18)/b16-11+

HIDE SMILES / InChI
Molecular Formula C14H16N4
Molecular Weight 240.3036
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/3656776 and http://synapse.koreamed.org/DOIx.php?id=10.4070/kcj.1984.14.2.373

Budralazine is a vasodilator. Budralazine is a direct-acting vasodilating agent that does not produce marked tachycardia. Hypotensive effect of Buterazine has being shown. Budralazine is reported as an ingredient of Buterazine in Japan.

Originator

Approval Year

Unknown
149124
Targets

Targets

Primary TargetPharmacologyConditionPotency
Modulator
846
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8583
Buterazine

Approved Use

Antihypertensive drug
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
50 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/3429588/
60 mg single, oral
dose: 60 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BUDRALAZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
90 mg 2 times / day multiple, oral
Recommended
Dose: 90 mg, 2 times / day
Route: oral
Route: multiple
Dose: 90 mg, 2 times / day
Sources:
https://books.google.ru/books?id=PghVgVDfF7UC&pg=PA316&lpg=PA316&dq=Buterazine+use&source=bl&ots=ecek3NMJTc&sig=PL9iCBDDaQG9C7pFXOO17hdGoZY&hl=en&sa=X&ved=0ahUKEwjt3dXMwonPAhXNOSwKHQUIBr0Q6AEIKTAD#v=onepage&q=Buterazine%20use&f=false Retrieved from Antihypertensive Drugs Today edited by Hideya Saito, Masaru Minami, p.316
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: unknown
Food Status: UNKNOWN
Sources:
https://books.google.ru/books?id=PghVgVDfF7UC&pg=PA316&lpg=PA316&dq=Buterazine+use&source=bl&ots=ecek3NMJTc&sig=PL9iCBDDaQG9C7pFXOO17hdGoZY&hl=en&sa=X&ved=0ahUKEwjt3dXMwonPAhXNOSwKHQUIBr0Q6AEIKTAD#v=onepage&q=Buterazine%20use&f=false Retrieved from Antihypertensive Drugs Today edited by Hideya Saito, Masaru Minami, p.316
Other AEs: Gastrointestinal upset...
Other AEs:
Gastrointestinal upset (5%)
Sources:
https://books.google.ru/books?id=PghVgVDfF7UC&pg=PA316&lpg=PA316&dq=Buterazine+use&source=bl&ots=ecek3NMJTc&sig=PL9iCBDDaQG9C7pFXOO17hdGoZY&hl=en&sa=X&ved=0ahUKEwjt3dXMwonPAhXNOSwKHQUIBr0Q6AEIKTAD#v=onepage&q=Buterazine%20use&f=false Retrieved from Antihypertensive Drugs Today edited by Hideya Saito, Masaru Minami, p.316
AEs

AEs

AESignificanceDosePopulation
Gastrointestinal upset 5%
90 mg 2 times / day multiple, oral
Recommended
Dose: 90 mg, 2 times / day
Route: oral
Route: multiple
Dose: 90 mg, 2 times / day
Sources:
https://books.google.ru/books?id=PghVgVDfF7UC&pg=PA316&lpg=PA316&dq=Buterazine+use&source=bl&ots=ecek3NMJTc&sig=PL9iCBDDaQG9C7pFXOO17hdGoZY&hl=en&sa=X&ved=0ahUKEwjt3dXMwonPAhXNOSwKHQUIBr0Q6AEIKTAD#v=onepage&q=Buterazine%20use&f=false Retrieved from Antihypertensive Drugs Today edited by Hideya Saito, Masaru Minami, p.316
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: unknown
Food Status: UNKNOWN
Sources:
https://books.google.ru/books?id=PghVgVDfF7UC&pg=PA316&lpg=PA316&dq=Buterazine+use&source=bl&ots=ecek3NMJTc&sig=PL9iCBDDaQG9C7pFXOO17hdGoZY&hl=en&sa=X&ved=0ahUKEwjt3dXMwonPAhXNOSwKHQUIBr0Q6AEIKTAD#v=onepage&q=Buterazine%20use&f=false Retrieved from Antihypertensive Drugs Today edited by Hideya Saito, Masaru Minami, p.316
PubMed

PubMed

TitleDatePubMed
Pre- and postsynaptic alpha-adrenergic effects of the antihypertensive drug budralazine.
1981
Patents

Patents

CA2386954A1
1
US2015352094
1
US8591941
6

Sample Use Guides

In Vivo Use Guide
The initial dose should be 90-120 mg. The maintenance dosage is usually 90-180 mg. The maintenance dosage is usually 90-180 mg per day, given in two or three divided doses.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:49:36 GMT 2025
Edited
by admin
on Mon Mar 31 18:49:36 GMT 2025
Record UNII
S0177QHV2B
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BUTERAZINE
Preferred Name English
BUDRALAZINE
INN   JAN   MI   WHO-DD  
INN  
Official Name English
Budralazine [WHO-DD]
Common Name English
budralazine [INN]
Common Name English
BUDRALAZINE [MI]
Common Name English
BUDRALAZINE [JAN]
Common Name English
4-METHYL-3-PENTEN-2-ONE (1-PHTHALAZINYL)HYDRAZONE
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C270
Created by admin on Mon Mar 31 18:49:36 GMT 2025 , Edited by admin on Mon Mar 31 18:49:36 GMT 2025
Code System Code Type Description
EPA CompTox
DTXSID00865833
Created by admin on Mon Mar 31 18:49:36 GMT 2025 , Edited by admin on Mon Mar 31 18:49:36 GMT 2025
PRIMARY
INN
3750
Created by admin on Mon Mar 31 18:49:36 GMT 2025 , Edited by admin on Mon Mar 31 18:49:36 GMT 2025
PRIMARY
DRUG CENTRAL
421
Created by admin on Mon Mar 31 18:49:36 GMT 2025 , Edited by admin on Mon Mar 31 18:49:36 GMT 2025
PRIMARY
ChEMBL
CHEMBL2107516
Created by admin on Mon Mar 31 18:49:36 GMT 2025 , Edited by admin on Mon Mar 31 18:49:36 GMT 2025
PRIMARY
CAS
36798-79-5
Created by admin on Mon Mar 31 18:49:36 GMT 2025 , Edited by admin on Mon Mar 31 18:49:36 GMT 2025
PRIMARY
MERCK INDEX
m1043
Created by admin on Mon Mar 31 18:49:36 GMT 2025 , Edited by admin on Mon Mar 31 18:49:36 GMT 2025
PRIMARY Merck Index
PUBCHEM
2463
Created by admin on Mon Mar 31 18:49:36 GMT 2025 , Edited by admin on Mon Mar 31 18:49:36 GMT 2025
PRIMARY
EVMPD
SUB05958MIG
Created by admin on Mon Mar 31 18:49:36 GMT 2025 , Edited by admin on Mon Mar 31 18:49:36 GMT 2025
PRIMARY
FDA UNII
S0177QHV2B
Created by admin on Mon Mar 31 18:49:36 GMT 2025 , Edited by admin on Mon Mar 31 18:49:36 GMT 2025
PRIMARY
MESH
C006153
Created by admin on Mon Mar 31 18:49:36 GMT 2025 , Edited by admin on Mon Mar 31 18:49:36 GMT 2025
PRIMARY
NCI_THESAURUS
C79901
Created by admin on Mon Mar 31 18:49:36 GMT 2025 , Edited by admin on Mon Mar 31 18:49:36 GMT 2025
PRIMARY
SMS_ID
100000088437
Created by admin on Mon Mar 31 18:49:36 GMT 2025 , Edited by admin on Mon Mar 31 18:49:36 GMT 2025
PRIMARY
WIKIPEDIA
Budralazine
Created by admin on Mon Mar 31 18:49:36 GMT 2025 , Edited by admin on Mon Mar 31 18:49:36 GMT 2025
PRIMARY
Related Record Type Details
Structure of BUDRALAZINE
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966